文献速递肝病消化道肿瘤与早癌

JOSD1通过调控PGAM1泛素化-乳酸化转换驱动肝细胞癌恶性进展

JOSD1 drives hepatocellular carcinoma malignancy by modulating the ubiquitination-lactylation switch on PGAM1.
PubMed 文献 · Gut · 2026-04-28

本研究结合多组学分析与细胞、动物及患者样本的功能机制实验,揭示去泛素化酶JOSD1在肝细胞癌(HCC)代谢重编程中的作用。JOSD1-AARS1轴协同调控PGAM1 K251位点的泛素化-乳酸化转换,稳定PGAM1并增强糖酵解,促进乳酸积累并抑制CD8+ T细胞浸润与功能。靶向抑制JOSD1可抑制肿瘤进展并与抗PD-1治疗协同延长生存。

要点

  • JOSD1高表达与HCC糖酵解及不良预后相关,促进恶性表型与糖酵解通量。
  • JOSD1-AARS1轴调控PGAM1 K251泛素化-乳酸化转换,稳定PGAM1并促乳酸积累。
  • 肝靶向抑制JOSD1可抑制肿瘤进展并与抗PD-1协同延长生存。

核心结论

  • JOSD1-AARS1轴通过调控PGAM1泛素化-乳酸化转换驱动HCC代谢重编程与免疫逃逸,靶向JOSD1是改善免疫治疗疗效的潜在策略。

研究设计与样本

  • 结合多组学分析与细胞系、动物模型及患者样本的功能和机制研究,表征JOSD1及其下游通路。

主要发现

  • JOSD1被鉴定为与糖酵解相关且与不良预后相关的基因,其过表达促进恶性表型并增强糖酵解通量。
  • JOSD1-AARS1轴协同调控PGAM1 K251残基的泛素化-乳酸化转换,稳定PGAM1、增强其酶活性并促进乳酸积累。
  • 该代谢转变损害CD8+ T细胞浸润与功能,促进免疫抑制。
  • 肝靶向抑制JOSD1有效抑制肿瘤进展,并与抗PD-1治疗协同延长生存。

临床怎么用

  • JOSD1可作为HCC代谢与免疫联合治疗的潜在靶点,肝靶向抑制JOSD1或可增敏抗PD-1治疗。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Metabolic reprogramming is a hallmark of hepatocellular carcinoma (HCC), enabling rapid tumour growth and immune evasion. Protein post-translational modification (PTM) crosstalk is a critical regulator of cellular processes; however, its contribution to metabolic reprogramming in HCC remains unclear. OBJECTIVE: To elucidate the function of the deubiquitinase JOSD1 in modulating PTM crosstalk and its impact on tumour glycolysis, progression and immunotherapy response in HCC. DESIGN: We combined multi-omics analyses with functional and mechanistic studies in cell lines, animal models and patient samples to characterise JOSD1 and its downstream pathways in HCC. RESULTS: JOSD1 was identified as a gene associated with glycolysis and correlated with a poor prognosis. Its over-expression promoted malignant phenotypes and enhanced glycolytic flux. Mechanistically, the JOSD1-AARS1 axis cooperatively regulates the ubiquitination-lactylation crosstalk at the K251 residue of PGAM1, thereby stabilising PGAM1, enhancing its enzymatic activity and promoting lactate accumulation. This metabolic shift impaired CD8+ T cell infiltration and function, promoting immune suppression. Therapeutically, liver-targeted inhibition of JOSD1 effectively suppressed tumour progression and synergised with anti-PD-1 therapy, leading to prolonged survival. CONCLUSION: The JOSD1-AARS1 axis regulates the ubiquitination-lactylation crosstalk on PGAM1, with JOSD1 acting as the critical upstream molecular switch that drives metabolic reprogramming and immune evasion in HCC. Targeting JOSD1 represents a promising therapeutic strategy to modulate tumour metabolism and improve immunotherapy efficacy.

来源:Gut,查看原文。版权归原作者所有。

引用

  1. Li Q, Yu K, Zhou S, et al. JOSD1 drives hepatocellular carcinoma malignancy by modulating the ubiquitination-lactylation switch on PGAM1. Gut. 2026. PMID: 42049490. doi:10.1136/gutjnl-2025-337331

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。